Background: Despite improvements in diagnostics and treatment, the clinical outcome of epithelial ovarian cancer remains poor over the last three decades. Recent high-throughput genomic studies have demonstrated ovarian cancer as a highly heterogeneous entity with distinctive molecular signatures among different or even within the same histotype. In this article, we review the molecular genetics of epithelial ovarian cancer and how they have been translated into modern clinical trials, as well as their implications in patient stratification for more targeted and personalized approaches.
Introduction
In 2016, an estimated 22 400 new cases and 14 200 deaths (ratio of 1.5 : 1) in the United States were reported for epithelial ovarian cancer (EOC) [1] . A similar incidence and death rate are observed in Europe. The latest statistics by World Health Organization suggests 65 538 and 42 704 deaths occurred in the year of 2012 [2] . Patients with early-stage disease (stage 1 and 2) are associated with an excellent 5-year survival rate after surgery and discretionary adjuvant chemotherapy [1, 3] . Unfortunately, the majority of EOC patients present with extensive peritoneal spread beyond the pelvic cavity (FIGO stage 3/4) that ascribes a considerably worse prognosis. For women diagnosed with advanced stage EOC, only 30% may survive more than 5 years, even after the most intensive care based on current clinical practices. Despite the emergence of targeted therapies such as bevacizumab-based antiangiogenesis therapy, most newly diagnosed EOC patients are universally subjected to a treatment paradigm consisting of aggressive cytoreductive (debulking) surgery followed by platinum and paclitaxel (Taxol)-based adjuvant chemotherapy. However, there is a broad spectrum of survival in women with EOC, including those women who cannot be surgically debulked and have a poor prognosis, to women who respond well to chemotherapy but die of recurrent disease and a small subset of patients who are long term survivors. Given the new discoveries in the molecular biology of ovarian cancer, stratification of ovarian cancer patients is needed for more effective treatment.
Early detection of ovarian cancer
Unfortunately, diagnosis of EOC at an early-stage (FIGO stage I/ II) has proven difficult through routine clinical screening, largely due to its asymptomatic nature and lack of accurate noninvasive screening strategies. The value of widespread screening using serum CA125 and transvaginal ultrasound, even under a multimodal strategy, has not been clearly demonstrated by the recently finalized UK Collaborative Trial of Ovarian Cancer Screening (UKCTOCS) trial, which employed more than 200 000 eligible subjects [4, 5] . Newer approaches include global proteomic analysis of the plasma from ovarian cancer patients compared with control patients with benign cysts. This approach has identified and validated multiple potential protein biomarkers, which are increased in the blood of ovarian cancer patients [6] . In parallel with this effort, high-throughput sequencing of cervical-vaginal fluid samples from ovarian cancer patients seeks to identify tumor specific mutated or amplified DNA [7, 8] . This approach relies on the pathologic data that a subset of tumors arises from the fallopian tube [9] [10] [11] . Nevertheless, the ultimate sensitivity and specificity of these technologies still need optimization to warrant their clinical applicability.
Preoperative stratification to maximize the benefit of cytoreduction Primary debulking surgery remains a pivotal part in the current management of EOC [12, 13] . However, EOC patients who have macroscopic (>1 cm) residual disease do not appear to benefit from primary cytoreduction. Conversely, universally applying neoadjuvant chemotherapy with interval debulking surgery has been demonstrated not a superior alternative [14] [15] [16] . The development of biomarkers that can reliably predict surgical outcome therefore becomes an unmet clinical need to stratify patients in advance for surgical options. While optimal cytoreduction is influenced by various factors including the tumor anatomical locations, surgical prowess and the fitness of the patients, the intrinsic tumor biology has been suggested equally important and profoundly influential to optimal cytoreduction-associated prognosis improvement. Conversely, suboptimally debulked diseases frequently present increased potentials of dissemination and/or chemoresistance. A meta-analysis of the transcriptional profiles from more than 1250 primary debulked EOCs has revealed a robust genomic signature with distinctive biological features dictating suboptimally debulked tumors. Subsequent biological annotation of the "debulking signature" has implicated hyperactivation of transforming growth factor (TGF)-b pathway underlying the overexpression of genes that render oncogenic modulation of both tumor and the tumor microenvironment, including epithelial-mesenchymal transition, metastasis, chemoresistance, desmoplastic stroma activation, and angiogenesis [17] (Figure 1 ). Despite the requirement of independent validation using prospective clinical specimens, identification of TGF-b signaling, which underlies the difficulty of optimal cytoreduction, may warrant the triage of patients through diagnostic laparoscopy specimens [18] . Such findings would further support the test of TGF-b inhibition as a potential approach for post-operative management of suboptimally debulked tumors, or in the neoadjuvant setting to increase the efficacy of neoadjuvant chemotherapy with interval debulking surgery and maximize the optimal cytoreduction rate. Inhibition of TGF-b signaling will not only decrease disseminated growth of tumor lesions but also sensitize these tumors to chemotherapy or recently emerged immunotherapies.
Stratification of patients by tumor histology
In line with pathological and clinical observations, recent genomic studies have demonstrated that different EOC histotypes have distinct molecular features and should be considered unique diseases [19, 20] . High-grade serous (HGSC), the most common histotype accounting for 60%-65% of EOCs has somatic TP53 mutations and a high degree of genomic instability [20, 21] . Extensive genomic gain and loss, rapid growth and aggressive dissemination are generally associated with high-grade serous EOC of which the epithelial cells lining fallopian tube fimbria are likely the primary precursors [9] [10] [11] . Importantly, low-grade serous tumors, comprising approximately 10% of the EOC, have important difference in genomics and distinctive expression profiles in comparison to its highgrade serous counterparts [22, 23] . Approximately 70% of lowgrade serous tumors have activating mutations in KRAS or BRAF, and consequential preponderance of the constitutively activated RAS/RAF/MAPK signaling pathway [22, 24] . Similarly, 75% of the rare mucinous tumors also present activating KRAS mutation and related transcriptional network [25] [26] [27] although they may represent ovarian metastases from other solid cancers such as gastrointestinal tumors [28, 29] . Endometrioid and clear cell ovarian cancer comprising 15%-20% of the EOC cases frequently develop from endometriosis or retrograde menstruation from the endometrium. Genome-wide mutational profiling has suggested frequent hyperactivation of PI3K/Akt pathway in both histotypes due to activating mutations of PI3KCA or deletion of PTEN in more than 50% of tumors [30] [31] [32] [33] . Specifically, endometrioid carcinomas are marked with activating mutations of CTNNB1 that result in constitutive, ligand-independent activation of oncogenic Wnt/b-catenin pathway [19, 34, 35] . In contrast, clear cell carcinomas are characterized by somatic inactivating mutations of the tumor suppressor ARID1A associated with chromatin remodeling [36, 37] . Evidence from transgenic murine models suggests that the loss of ARID1A coupled with PI3K/Akt activation determines the histopathology and molecular signature of clear cell ovarian carcinoma [38] .
The molecular diversity among different EOC histotypes would strongly discourage the treatment of EOC as a single disease entity without the stratification of different histological or molecular subtypes. In seven GCIG (Gynecologic Cancer Intergroup) randomized trials (8704 patients) [39] Genes overexpressed in tumors that were subsequently suboptimally debulked are labeled in red. Genes overexpressed in tumors with optimal cytoreduction are labeled in blue. Genes with predictive power toward poor prognosis based on the meta-analysis are highlighted with pink borders. Red broken arrows indicate direct stimulatory modification. Green arrows indicate patients) [40] , advanced stage EOC patients were subjected to platinum/taxane combinations regardless of the tumor histotype. Retrospective reviewing of these trials has demonstrated that the serous and endometrioid cancers experienced the best survival from the conventional cytotoxic chemotherapy, while clear cell and mucinous tumor showed poorer outcome and a twofold to fourfold decrease in progression-free and overall survival compared with HGSCs. In addition, the recognition of the unique biology and molecular features of tumor with different histotype and grade has given rise to tumor specific trials. Therapeutic targeting of hyperactivated Ras/Raf/MEK/Erk pathway has been proposed as a novel approach to target low-grade serous EOCs. The recent phase II clinical trial using selumetinib (AZD6244), an oral non-ATP competitive small molecule inhibitor of MEK1/ 2, has demonstrated significant benefit with increased objective response rate and decreased toxicity compared with conventional cytotoxic agents (GOG-239) [41] . Hyperactivation of PI3K/Akt/ mTOR pathway has been utilized as the basis in another phase II trial specifically targeting ovarian clear cell carcinoma (GOG-0268). Preclinical testing suggest mTOR inhibition has strong targeting efficacy against clear cell carcinoma, regardless of the tumor platinum sensitivity [42] [43] [44] . The GOG-0268 trial examines temsirolimus, a strong inhibitor against mTOR1 and 2, in combination with carboplatin and paclitaxel followed by temsirolimus consolidation as a first-line therapy for patients with advanced stage disease. In addition to genomic aberrance, analyses of the transcriptomic signature of clear cell carcinoma have also yielded valuable therapeutic targets. Several key modulators have been identified to be biologically responsible for the revolving enhancement of IL6/STAT3 signaling or involved in response to hypoxia and metabolic stress [by Hypoxia induced factor 1a (HIF-1a), HIF-2a/Endothelial PAS domain containing protein 1 (EPAS1) and enolase 1 (ENO-1)], generating a highly angiogenic phenotype that hallmarks clear cell ovarian carcinoma [45] [46] [47] (Figure 2 ). These data informed the design of a currently ongoing phase II clinical trial using Sunitinib (GOG-0254), a pan receptor tyrosine kinase inhibitor that primarily targets tumor microvasculature through the inhibition of angiogenic signals from vascular endothelial growth factor (VEGF), platelet-derived growth factor (PDGF), and ckit [46] . The initial report suggested the utility of Sunitinib as a second-or third-line treatment of patients with persistent or recurrent clear cell ovarian carcinoma [48] . In addition, amplification and overexpression of receptor tyrosine kinases including MET [49, 50] and ERBB2 [51] may provide additional novel therapeutic approaches in the management of clear cell ovarian cancers.
Stratification of high-grade serous ovarian cancer with HRD
Genomic studies have reinforced the centrality of inactivating TP53 mutations and disruption of homologous recombinant directed DNA repair in high-grade serous ovarian cancers (HGSC) [21] . Approximately 50% of HGSC exhibit homologous recombination deficiency (HRD), which can be attributed by various mechanisms including germline mutation, somatic mutation or epigenetic silencing of BRCA1, BRCA2 [52, 53] and other Fanconi anemia pathway components (such as BRIP1, BARD1, RAD51B and RAD51C) [8, [54] [55] [56] [57] that guard genomic integrity by rendering error-free homologous recombinant directed DNA repair [21, 58, 59] . Germline HRD renders tumor predisposition in approximately 20% of HGSC patients, yet is associated with a better clinical outcome ( Figure 3A and B [60, [64] [65] [66] . Similarly, the recently completed randomized, placebo-controlled, phase III trial of PARP1/2 inhibitor niraparib (ENGOT-OV16/NOVA) have suggested significant benefit for both platinum-sensitive and platinum-resistant ovarian cancer patients with continuing niraparib treatment after frontline chemotherapy [67] . Notably, niraparib has provided significant clinical benefit regardless of BRCA status, which can be potentially attributed to aggregated genotoxic stress resulted from PARP inhibition mediated accumulation of single-strand DNA breaks. Nevertheless, more niraparib-related benefit has been suggested in a subset of patients with germline BRCA1/2 mutation, and even for patients without BRCA1/2 mutation yet eliciting HRD ( Figure 3C ). Reliable prediction of therapeutic indication is currently under active development, including the measurement of the genome-wide consequences of HRD or genomic scarring to stratify patients who will mostly likely respond to PARP inhibitors [68] [69] [70] . Challenges and the future perspective for high-grade serous ovarian cancer
Except for TP53 and BRCA1/2, actionable point mutations in well-accepted oncogenes or tumor suppressive genes are relatively infrequent in HGSC [21] . Instead, a high-degree of chromosome instability prevails in HGSC and leads to extensive DNA gains and losses, which activate oncogenes or inactivate tumor suppressors through gene amplification, deletion, or translocation to drive early-stage tumorigenesis and the development of chemoresistance [71] [72] [73] . Even so, identification of novel 'druggable' targets with high-frequency copy number variation remains challenging even after the completion of several comprehensive genomic studies. Moreover, extensive genomic instability induces substantial clonal diversity in treatment naïve HGSCs.
Several genomic analyses have revealed extensive yet different DNA copy number variations and resultant dysregulation of gene expression profiles within the same tumor, which provide molecular background for adaptation and development of chemoresistance, a hallmark of HGSC that ultimately determines the poor patient outcome [74] [75] [76] . Interval laparoscopic sampling during the treatment course or upon recurrence is thus warranted to delineate the molecular mechanism of resistance so that personalized target therapy can be designed to better combat tumor relapse. Despite the chaotic genomics in HGSC, recent genomic analyses, in particular The Cancer Genome Atlas [21] , have suggested the power of identifying novel biomarkers critical for the clinicopathological features or prognostic outcomes of HGSC. Through integrative analyses of genomic data from different platforms, 
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Annals of Oncology such as the exome, methylome and transcriptome, we have previously identified several candidate genes to provide new modality of ovarian cancer treatment [77] . One of such genes is fibroblast growth factor (FGF) 18, which is amplified and overexpressed to drive tumorigenesis in a subset of HGSCs [78] . Subsequent biological validation has further suggested FGF18 confers a proinflammatory phenotype through nuclear factor-jB-dependent upregulation of cytokine production to manifest oncogenic impacts. Furthermore, HGSC cancer cells with elevated FGF18 foster a tumor microenvironment characterized by enhanced angiogenesis and augmented tumor-associated macrophage infiltration and M2 polarization, which reciprocally augment the proinflammatory status of HGSC cells to form a positive feedback loop. In addition to FGF18, the critical role of FGF signaling in the tumorigenesis of HGSC can also be suggested by several lines of evidence. One of the FGF18 receptors FGFR4, which resides at the same amplicon as FGF18, has been independently demonstrated to be critical in mediating angiogenesis and poor prognosis [79] . In addition, the TCGA project has suggested 12.5% HGSC patients carry focal amplification of the tyrosine adaptor protein FRS2, which is required to relay signaling from all four FGF receptors to downstream cascades [21] . The oncogenic role of FRS2 in HGSC has been subsequently confirmed by Project Achilles, a systematic effort to identify cancer dependencies at genome-wide scale using shRNA knock-down-based screening [80] . Taken together, the availability of effective approaches to inhibit FGF signaling [81] may provide a novel targeted therapy for a subset of HGSC patients with specific hyperactivation in this pathway.
Owing to the complex genomics in HGSC, targeting genomically intact cellular components comprising tumor microenvironment have recently come into the spotlight. Encouraging results have been obtained via antiangiogenesis therapy. Application of a humanized VEGFA neutralizing antibody bevacizumab in a firstline setting with platinum/paclitaxel therapy has demonstrated improvement in progression-free survival from two independent phase III clinical trials GOG-0218 and ICON7 [82, 83] . The benefit of bevacizumab in platinum-resistant recurrent ovarian cancer has also been suggested by the AURELIA trial [84] . However, the benefit of universal bevacizumab administration tends to be modest in the above trials, making it an urgent need to identify biomarkers predictive of bevacizumab response [85, 86] . Alternatively, combinations of angiogenic inhibitors and other targeted treatments may be clinically relevant, as demonstrated by the recent phase II clinical trial using the VEGFR inhibitor cedarinib and the PARP inhibitor olarparib [87] .
Recently, immune therapy including therapeutic vaccines, CAR-T cells or immune check point inhibition has become another promising area for the management of HGSCs [88, 89] . Numerous studies have confirmed the prognostic significance of intraepithelial CD8þ T cells [90] , which recognize both shared tumor antigens (such as Her2, CTAG1B, mesothelin, and [59] . (C) Estimated hazard ratio (progression-free survival) for niraparib versus placebo as maintenance treatment among patients with a germline BRCA mutation, those without a germline BRCA mutation in whom tumors were found to have homologous recombination deficiency (HRD), and those without a germline BRCA mutation. All arms have a two-sided P < 0.0001, which was calculated by stratified log-rank test. Adapted from Mirza et al. [67] .
hTERT) and neoantigens from aberrant genomic alteration. One of the major obstacles lies in the immunosuppressive phenotype frequently presented in HGSC, which overexpress a plethora of factors such as cytokines [interleukin (IL)-10, TGF-b], immune surveillance blockers (CD47), metabolite disruptors (arginase, IDO1), and immune check point molecules (PDL1, CTLA4) to mediate immune evasion. Interestingly, transcriptomic profiling studies have revealed an immunoreactive molecular subtype in a subset of HGSC, which is associated with relatively better outcome [73, 91] . Such signature thus provides an opportunity to stratify patients to appropriate immune therapy options. Another potential consideration is HGSC only has an intermediate global mutation load, which may affect the abundance of neoantigens based on point mutation [92, 93] . In this regard, enhanced immune response may be expected in tumors defective of DNA repair pathway. In fact, it has been demonstrated that the tumor infiltrating lymphocytes are particularly prominent in BRCA1 mutated HGSCs [94, 95] .
Discussion Conclusion
Accumulating knowledge has suggested a highly complex genomic landscape in EOC. The extensive heterogeneity in molecular abnormalities implies there may not be a one-size fits all solution for the clinical management of EOC. Anti-neoplastic treatment can significantly benefit from comprehensive genomic studies by providing a better understanding of the genomic aberrance and consequential molecular dysregulation underlying tumorigenesis and chemoresistance. While large-scale genomic studies have presented opportunities for identification of novel therapeutic biomarkers to warrant personalized treatment with improved outcomes, comprehensive validation at both bioinformatical and biological levels as well as clinical studies are essential to translate the findings from genomic profiling studies. Furthermore, appropriate integration of genomic profiles with large-scale studies of metabolome, proteome and immune repertoire [95] [96] [97] [98] [99] [100] would generate valuable information to delineate the biological consequences of an identified molecular abnormality to warrant its clinical potential as a novel therapeutic target.
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